C4 Therapeutics Q4 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy CCCC?
Source: seekingalpha
- Strong Earnings Report: C4 Therapeutics reported a Q4 GAAP EPS of -$0.18, beating expectations by $0.14, indicating a positive trend in the company's profitability improvement efforts.
- Significant Revenue Growth: The company achieved Q4 revenue of $11 million, representing a 111.5% year-over-year increase, exceeding market expectations by $6.52 million, reflecting strong product demand and successful market expansion.
- Increased Cash Reserves: As of December 31, 2025, C4's cash, cash equivalents, and marketable securities totaled $297.1 million, a significant increase from $199.8 million as of September 30, 2025, enhancing the company's financial stability.
- Year-over-Year Comparison: Compared to $267.3 million on December 31, 2024, the increase in cash reserves indicates ongoing improvements in the company's financial management and operational efficiency, further supporting future R&D and market expansion plans.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CCCC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CCCC
About CCCC
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
C4 Therapeutics Partners with Roche to Develop Novel Cancer Drugs
- New Drug Collaboration: C4 Therapeutics (CCCC) has announced a new partnership with long-time collaborator Roche (RHHBY) to develop a novel class of cancer drugs known as degrader-antibody conjugates (DACs), combining antibody-drug conjugation (ADC) with targeted protein degradation (TPD) to advance two DAC programs against undisclosed oncology targets.
- Funding and Milestones: Under the agreement, C4 is eligible to receive $20 million from Roche for the two programs, with additional payments if Roche opts for a third program, alongside potential milestone payments exceeding $1 billion, contingent on achieving specific R&D, regulatory, and commercial targets.
- Long-term Partnership: Since signing a licensing deal in 2016, C4 Therapeutics and Roche have collaborated for a decade in targeted protein degradation research, with CEO Andrew Hirsch noting that this partnership has established a new modality for cancer treatment.
- Market Potential and Strategic Importance: This collaboration not only highlights C4's innovative capabilities in cancer drug development but also has the potential to significantly enhance the company's competitiveness and market share in the biopharmaceutical sector through the successful development of new drugs.
See More
C4 Therapeutics Expands Partnership with Roche for Cancer Treatments
- Stock Surge: C4 Therapeutics shares rose 5% in pre-market trading on Thursday, reflecting positive market sentiment regarding the company's expanded collaboration with Swiss pharmaceutical giant Roche, indicating investor confidence in future cancer treatment developments.
- Collaboration Focus: The partnership will concentrate on developing emerging cancer therapies using degrader-antibody conjugates (DAC) and targeted protein degradation (TPD) processes, highlighting the company's strategic positioning in innovative drug development.
- Financial Gains: Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and has the potential to earn over $1 billion in milestone payments, along with tiered royalties on future sales, significantly enhancing the company's financial stability.
- Market Potential: The collaboration aims to develop DAC therapies targeting undisclosed cancer indications, underscoring the company's potential impact in the cancer treatment market and future growth opportunities.
See More
C4 Therapeutics Partners with Roche for DAC Development
- Collaboration Agreement: C4 Therapeutics has entered into a new collaboration with Roche to advance research in degrader-antibody conjugates (DACs), focusing on developing DACs against undisclosed oncology targets, highlighting strategic synergy in cancer treatment.
- Financial Support: C4 will receive a $20 million upfront payment and is eligible for over $1 billion in discovery, regulatory, and commercial milestone payments, significantly enhancing the company's financial stability and R&D capabilities.
- Technology Platform Utilization: C4 will leverage its TORPEDO platform to design degrader payload candidates, while Roche will select and design the antibody, showcasing complementary strengths that could accelerate drug development timelines.
- Positive Market Reaction: In pre-market trading on Nasdaq, C4 shares rose 2.44% to $2.97, reflecting market optimism regarding the collaboration's prospects, which may drive future stock performance.
See More
C4 Therapeutics Enhances Ongoing Partnership with Roche via New Collaboration to Explore and Develop Degrader-Antibody Conjugates (DACs)
- Partnership Expansion: Therapeutics has expanded its long-term partnership with Roche through a new collaboration agreement.
- Research Focus: The collaboration will focus on discovering and developing degrader-antibody conjugates (DACs).
See More
C4 Therapeutics Q4 Earnings Exceed Expectations
- Strong Earnings Report: C4 Therapeutics reported a Q4 GAAP EPS of -$0.18, beating expectations by $0.14, indicating a positive trend in the company's profitability improvement efforts.
- Significant Revenue Growth: The company achieved Q4 revenue of $11 million, representing a 111.5% year-over-year increase, exceeding market expectations by $6.52 million, reflecting strong product demand and successful market expansion.
- Increased Cash Reserves: As of December 31, 2025, C4's cash, cash equivalents, and marketable securities totaled $297.1 million, a significant increase from $199.8 million as of September 30, 2025, enhancing the company's financial stability.
- Year-over-Year Comparison: Compared to $267.3 million on December 31, 2024, the increase in cash reserves indicates ongoing improvements in the company's financial management and operational efficiency, further supporting future R&D and market expansion plans.
See More
C4 Therapeutics Stock Analysis and Outlook
- Strong Analyst Confidence: As of February 16, 2026, all analysts covering C4 Therapeutics (NASDAQ:CCCC) remain bullish, with a consensus price target of $7.00 indicating a 270.37% upside, reflecting strong belief in its primary degrader, Cemsidomide.
- Clinical Milestone Planning: On January 14, 2026, C4 Therapeutics outlined key clinical and regulatory milestones through 2028, including plans for an NDA submission for Cemsidomide by year-end 2028 and initial ORR data expected in 2H 2027, indicating significant progress in treating multiple myeloma.
- Trial Launch and Collaborations: C4T plans to launch the Phase 2 MOMENTUM trial in Q1 2026 for fourth-line or later patients, with a Phase 1b combination study involving elranatamab starting in Q2 2026, and a Phase 3 trial anticipated by early 2028, showcasing its proactive clinical development strategy.
- Multiple Collaborations and Growth Potential: Partnerships with Merck KGaA, Roche, and Biogen position C4 Therapeutics to file up to three INDs by 2028 from its neuro- and inflammation programs, enhancing its competitive edge in oncology and signaling robust growth potential.
See More
C4 Therapeutics Partners with Roche to Develop Novel Cancer Drugs
- New Drug Collaboration: C4 Therapeutics (CCCC) has announced a new partnership with long-time collaborator Roche (RHHBY) to develop a novel class of cancer drugs known as degrader-antibody conjugates (DACs), combining antibody-drug conjugation (ADC) with targeted protein degradation (TPD) to advance two DAC programs against undisclosed oncology targets.
- Funding and Milestones: Under the agreement, C4 is eligible to receive $20 million from Roche for the two programs, with additional payments if Roche opts for a third program, alongside potential milestone payments exceeding $1 billion, contingent on achieving specific R&D, regulatory, and commercial targets.
- Long-term Partnership: Since signing a licensing deal in 2016, C4 Therapeutics and Roche have collaborated for a decade in targeted protein degradation research, with CEO Andrew Hirsch noting that this partnership has established a new modality for cancer treatment.
- Market Potential and Strategic Importance: This collaboration not only highlights C4's innovative capabilities in cancer drug development but also has the potential to significantly enhance the company's competitiveness and market share in the biopharmaceutical sector through the successful development of new drugs.
See More
C4 Therapeutics Expands Partnership with Roche for Cancer Treatments
- Stock Surge: C4 Therapeutics shares rose 5% in pre-market trading on Thursday, reflecting positive market sentiment regarding the company's expanded collaboration with Swiss pharmaceutical giant Roche, indicating investor confidence in future cancer treatment developments.
- Collaboration Focus: The partnership will concentrate on developing emerging cancer therapies using degrader-antibody conjugates (DAC) and targeted protein degradation (TPD) processes, highlighting the company's strategic positioning in innovative drug development.
- Financial Gains: Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and has the potential to earn over $1 billion in milestone payments, along with tiered royalties on future sales, significantly enhancing the company's financial stability.
- Market Potential: The collaboration aims to develop DAC therapies targeting undisclosed cancer indications, underscoring the company's potential impact in the cancer treatment market and future growth opportunities.
See More
C4 Therapeutics Partners with Roche for DAC Development
- Collaboration Agreement: C4 Therapeutics has entered into a new collaboration with Roche to advance research in degrader-antibody conjugates (DACs), focusing on developing DACs against undisclosed oncology targets, highlighting strategic synergy in cancer treatment.
- Financial Support: C4 will receive a $20 million upfront payment and is eligible for over $1 billion in discovery, regulatory, and commercial milestone payments, significantly enhancing the company's financial stability and R&D capabilities.
- Technology Platform Utilization: C4 will leverage its TORPEDO platform to design degrader payload candidates, while Roche will select and design the antibody, showcasing complementary strengths that could accelerate drug development timelines.
- Positive Market Reaction: In pre-market trading on Nasdaq, C4 shares rose 2.44% to $2.97, reflecting market optimism regarding the collaboration's prospects, which may drive future stock performance.
See More
C4 Therapeutics Enhances Ongoing Partnership with Roche via New Collaboration to Explore and Develop Degrader-Antibody Conjugates (DACs)
- Partnership Expansion: Therapeutics has expanded its long-term partnership with Roche through a new collaboration agreement.
- Research Focus: The collaboration will focus on discovering and developing degrader-antibody conjugates (DACs).
See More
C4 Therapeutics Q4 Earnings Exceed Expectations
- Strong Earnings Report: C4 Therapeutics reported a Q4 GAAP EPS of -$0.18, beating expectations by $0.14, indicating a positive trend in the company's profitability improvement efforts.
- Significant Revenue Growth: The company achieved Q4 revenue of $11 million, representing a 111.5% year-over-year increase, exceeding market expectations by $6.52 million, reflecting strong product demand and successful market expansion.
- Increased Cash Reserves: As of December 31, 2025, C4's cash, cash equivalents, and marketable securities totaled $297.1 million, a significant increase from $199.8 million as of September 30, 2025, enhancing the company's financial stability.
- Year-over-Year Comparison: Compared to $267.3 million on December 31, 2024, the increase in cash reserves indicates ongoing improvements in the company's financial management and operational efficiency, further supporting future R&D and market expansion plans.
See More
C4 Therapeutics Stock Analysis and Outlook
- Strong Analyst Confidence: As of February 16, 2026, all analysts covering C4 Therapeutics (NASDAQ:CCCC) remain bullish, with a consensus price target of $7.00 indicating a 270.37% upside, reflecting strong belief in its primary degrader, Cemsidomide.
- Clinical Milestone Planning: On January 14, 2026, C4 Therapeutics outlined key clinical and regulatory milestones through 2028, including plans for an NDA submission for Cemsidomide by year-end 2028 and initial ORR data expected in 2H 2027, indicating significant progress in treating multiple myeloma.
- Trial Launch and Collaborations: C4T plans to launch the Phase 2 MOMENTUM trial in Q1 2026 for fourth-line or later patients, with a Phase 1b combination study involving elranatamab starting in Q2 2026, and a Phase 3 trial anticipated by early 2028, showcasing its proactive clinical development strategy.
- Multiple Collaborations and Growth Potential: Partnerships with Merck KGaA, Roche, and Biogen position C4 Therapeutics to file up to three INDs by 2028 from its neuro- and inflammation programs, enhancing its competitive edge in oncology and signaling robust growth potential.
See More
